Combinations of PARP inhibitors with drugs that inhibit HR may sensitise EOC with a primary or secondary HR proficiency to PARP inhibitors and potentially expand their use beyond HR-deficient ovarian cancers. The gene discussed is PARP1; the disease is ovarian cancer.